A comprehensive review published in 2026 in Frontiers in Cell and Developmental Biology brings together the current science on a process that gets far less attention than it deserves: the aging of the body’s own stem cells. Every tissue depends on a small resident population of stem cells to maintain itself throughout life — and the review’s central point is that this population doesn’t simply sit in reserve as we age. It deteriorates, in ways that are now well enough understood to start asking what can be done about it.
A Hallmark, Not a Symptom
This deterioration is now formally recognized as one of the hallmarks of the aging process itself — not a downstream consequence of aging, but one of its root mechanisms. As stem cell pools decline, so does the tissue’s ability to replace worn-out cells and respond to injury, which helps explain why regenerative capacity drops so unevenly across the body as people get older.
Hematopoietic stem cells offer a curious twist on this pattern. Their numbers actually rise with age — but their function deteriorates, and their output skews toward certain immune cell lineages at the expense of others. More cells, doing their job worse. It’s a reminder that stem cell aging isn’t simply about counting cells; it’s about whether those cells can still do what they’re supposed to do.
Two Very Different Biological Identities
Adult, tissue-resident stem cells are multipotent — already committed to producing a limited set of cell types for the tissue they live in. That commitment comes at a cost: they age alongside the tissue around them, accumulating the same DNA damage, the same shortening telomeres, the same epigenetic drift, while the environment they depend on — their niche — deteriorates in parallel. They have no internal mechanism to reset any of this.
Pluripotent stem cells are different from the moment they’re created. Their broad developmental potential gets most of the public attention, but for adult patients, the more clinically relevant property is what their paracrine signals — their exosomes — can do to the aging stem cells already present in the body. Senescent stem cells turn out to be an especially receptive target for this kind of signaling: they haven’t died or disappeared, they’ve simply stopped responding to the cues that once kept them active, which is exactly the kind of state a well-matched signal can reverse.
Restoration Across Tissues
This is where PSC paracrine signaling finds its most compelling target: the aging stem cells the patient already has. This isn’t a single, isolated finding. It shows up independently, through different mechanisms, in different labs, in different tissues — which is what makes it a pattern worth paying attention to rather than a one-off result.
In the brain, researchers found that small extracellular vesicles from pluripotent stem cells rejuvenated senescent hippocampal neural stem cells in aged mice by delivering SMAD4 and SMAD5 proteins, which activate a factor called MYT1. MYT1 in turn lowers Egln3 and switches on Sirt1 — a pathway well known for its role in cellular longevity. The functional result wasn’t subtle: aged mice regained neural stem cell self-renewal and neuron production, and measurably reversed cognitive decline. Notably, this happened via systemic administration — a reminder of how far-reaching paracrine signaling can be, reaching a tissue as protected as the brain without the source cells ever needing to arrive there themselves.
A separate study, working in a vascular dementia model, found the same population of hippocampal neural stem cells rejuvenated through an entirely different route — lysosome activation, driven by a cluster of microRNAs that dial down an aging-associated growth pathway called mTORC1. Two independent teams, two different mechanisms, the same underlying result: pluripotent stem cell signaling waking up dormant neural stem cells and restoring their capacity to do their job.
The pattern extends well beyond the brain. In bone, pluripotent stem cell-derived signaling was shown to rejuvenate senescent bone marrow mesenchymal stem cells directly, reducing age-related bone loss — the same resident population responsible for maintaining bone density throughout life. And more broadly, exosomes carrying two specific microRNAs — miR-15b-5p and miR-290a-5p — reversed senescence in aged fibroblasts and improved markers of aging in the kidney, liver, and spleen of older mice, by silencing a growth-signaling pathway that becomes overactive with age.
Taken together, these findings point to something more specific than general anti-aging signaling: a repeated, mechanistically distinct pattern of PSC signals re-engaging the dormant regenerative machinery already present in aged tissue.
What This Means for How We Think About Repair
The evidence above points to a specific and, for an aging body, deeply useful idea. The patient’s own stem cell populations haven’t disappeared with age; they’ve gone quiet, worn down by the same accumulated damage affecting every other cell around them. What these studies show is that the right signal can wake that capacity back up.
This reframes what “rejuvenation” means in practice. It isn’t only about the new signals a PSC-based therapy introduces — it’s about what those signals restore in cells the patient has been carrying, and losing the use of, for years.
Where the Evidence Stands Today
It’s worth being precise about what this evidence does and doesn’t yet show. All of the mechanistic studies described here were conducted in mouse and rat models — the biology is well characterized, but human clinical trial data specifically confirming this same resident-stem-cell rejuvenation pathway is still an open frontier. What we can say with confidence is that the mechanism is real, it has been independently replicated across different research groups and different tissue types, and it offers a coherent explanation for the outcomes — including in the brain — that Blast treatments deliver.
References
- Stem cell dysfunction and rejuvenation strategies in ageing: emerging advances in regenerative medicine. Frontiers in Cell and Developmental Biology (2026). doi.org/10.3389/fcell.2026.1830358
- Hu G, Xia Y, Chen B, et al. ESC-sEVs rejuvenate aging hippocampal NSCs by transferring SMADs to regulate the MYT1-Egln3-Sirt1 axis. Molecular Therapy 29(1), 103–120 (2021). doi.org/10.1016/j.ymthe.2020.09.034
- Hu G, Xia Y, Zhang J, et al. ESC-sEVs rejuvenate senescent hippocampal NSCs by activating lysosomes to improve cognitive dysfunction in vascular dementia. Advanced Science 7, 1903330 (2020). doi.org/10.1002/advs.201903330
- Gong LZ, Chen B, Zhang JT, et al. Human ESC-sEVs alleviate age-related bone loss by rejuvenating senescent bone marrow-derived mesenchymal stem cells. Journal of Extracellular Vesicles 9(1), 1800971 (2020). doi.org/10.1080/20013078.2020.1800971
- Yu L, Wen H, Liu C, et al. Embryonic stem cell-derived extracellular vesicles rejuvenate senescent cells and antagonize aging in mice. Bioactive Materials 29, 85–97 (2023). doi.org/10.1016/j.bioactmat.2023.06.011
